Centre for Dementia Research, Leeds Beckett University, Leeds, UK.
Wolfson Centre for Aged Related Diseases, King's College London, London, UK.
Int Psychogeriatr. 2020 Jan;32(1):75-85. doi: 10.1017/S1041610219000279.
Behaviours associated with agitation are common in people living with dementia. The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item scale widely used to assess agitation completed by a proxy (family carer or staff member). However, proxy informants introduce possible reporting bias when blinding to the treatment arm is not possible, and potential accuracy issues due to irregular contact between the proxy and the person with dementia over the reporting period. An observational measure completed by a blinded researcher may address these issues, but no agitation measures with comparable items exist.
Development and validation of an observational version of the CMAI (CMAI-O), to assess its validity as an alternative or complementary measure of agitation.
Fifty care homes in England.
Residents (N = 726) with dementia.
Two observational measures (CMAI-O and PAS) were completed by an independent researcher. Measures of agitation, functional status, and neuropsychiatric symptoms were completed with staff proxies.
The CMAI-O showed adequate internal consistency (α = .61), criterion validity with the PAS (r = .79, p = < .001), incremental validity in predicting quality of life beyond the Functional Assessment Staging of Alzheimer's disease (β = 1.83, p < .001 at baseline) and discriminant validity from the Neuropsychiatric Inventory Apathy subscale (r = .004, p = .902).
The CMAI-O is a promising research tool for independently measuring agitation in people with dementia in care homes. Its use alongside the CMAI could provide a more robust understanding of agitation amongst residents with dementia.
与激越相关的行为在痴呆患者中很常见。Cohen-Mansfield 激越量表(CMAI)是一种广泛用于评估激越的 29 项量表,由代理人(家庭护理员或工作人员)完成。然而,当无法对治疗组进行盲法时,代理人报告可能会引入偏倚,并且由于代理人和痴呆症患者在报告期间的接触不规律,可能会出现准确性问题。由盲法研究人员完成的观察性测量可能会解决这些问题,但不存在具有可比项目的激越测量方法。
开发和验证 CMAI 的观察版本(CMAI-O),以评估其作为激越替代或补充测量方法的有效性。
英格兰的 50 家养老院。
患有痴呆症的居民(N = 726)。
由独立研究人员完成两项观察性测量(CMAI-O 和 PAS)。由工作人员代理人完成激越、功能状态和神经精神症状的测量。
CMAI-O 显示出足够的内部一致性(α =.61),与 PAS 的标准效度(r =.79,p <.001),以及在预测生活质量方面的增量效度(在基线时,超过阿尔茨海默病功能评估分期的β = 1.83,p <.001)和与神经精神疾病问卷淡漠分量表的判别效度(r =.004,p =.902)。
CMAI-O 是一种有前途的研究工具,可用于独立测量养老院中痴呆症患者的激越。它与 CMAI 一起使用可以更全面地了解痴呆症患者的激越情况。